Skip to main content
Premium Trial:

Request an Annual Quote

Illumina, Bristol-Myers Squibb Partner on Companion Dx Development for Immunotherapy

NEW YORK (GenomeWeb) – Illumina and Bristol-Myers Squibb announced after the close of the market Friday that they will collaborate on developing and commercializing companion diagnostics to support BMS' oncology drug pipeline.

The companies plan to develop a diagnostic version of Illumina's TruSight Oncology 500, an assay being developed to target most of the known biomarkers for cancer drugs, including tumor mutation burden and miscrosatellite instability. The panel will run on Illumina's NextSeq 550Dx.

"Through our deep understanding of cancer biology and emerging research, we recognize the importance for physicians to know each patient's biomarker status to help fight their cancer in a more personalized way," Saurabh Saha, senior vice president, global head of translational medicine at Bristol-Myers Squibb, said in a statement. "We are excited to partner with Illumina to pursue development of diagnostics that can help predict which patients will have the potential to benefit most from our immunotherapies."

Earlier this week, Illumina announced a separate partnership with Loxo Oncology to develop a pan-cancer companion diagnostic with a different assay, the TruSight 170 panel. 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.